Integra Lifesciences Holdings (IART) Asset Writedowns and Impairment (2013 - 2025)

Integra Lifesciences Holdings has reported Asset Writedowns and Impairment for 9 years, with the latest figure at $511.4 million in Q2 2025.

• Quarterly Asset Writedowns and Impairment rose 10038.08% year-over-year to $511.4 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $511.4 million (up 2552.31% YoY) and the FY2025 annual result came in at $511.4 million, up 4088.43% from the prior year.
• Asset Writedowns and Impairment rose to $511.4 million in Q2 2025 per IART's latest filing, from $36000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $511.4 million in Q2 2025 and troughed at $36000.0 in Q4 2024.
• A 3-year average of $88.9 million and a median of $6.1 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 10038.08% in 2025, down 10038.08% in 2025.
• Over 3 years, Asset Writedowns and Impairment stood at $2.8 million in 2021, then sank by 98.69% to $36000.0 in 2024, then jumped by 1420358.33% to $511.4 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $511.4 million, $36000.0, and $7.1 million for Q2 2025, Q4 2024, and Q3 2024 respectively.